June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Increase of lens power by deglycation as potential presbyopia treatment
Author Affiliations & Notes
  • Elisabeth Hermine Van Aken
    Head and Skin, Universiteit Gent, Gent, Belgium
  • Jeroen Beeckman
    faculty of engineering and architecture, Universiteit Gent, Gent, Belgium
  • Jonas Himpe
    Diagnostic sciences, Universiteit Gent, Gent, Belgium
  • Nezahat Bostan
    Tissuebank, Universitair Ziekenhuis Antwerpen Universitair Forensisch Centrum, Edegem, Belgium
  • Manon Huizing
    Tissuebank, Universitair Ziekenhuis Antwerpen Universitair Forensisch Centrum, Edegem, Belgium
  • Joris Delanghe
    Diagnostic sciences, Universiteit Gent, Gent, Belgium
  • Footnotes
    Commercial Relationships   Elisabeth Van Aken None; Jeroen Beeckman None; Jonas Himpe None; Nezahat Bostan None; Manon Huizing None; Joris Delanghe None
  • Footnotes
    Support  IOF F2021STARTT039
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2502. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elisabeth Hermine Van Aken, Jeroen Beeckman, Jonas Himpe, Nezahat Bostan, Manon Huizing, Joris Delanghe; Increase of lens power by deglycation as potential presbyopia treatment. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2502.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To measure human lens power after treatment of lenses with the deglycating agent fructosyl amino acid oxidase (FAOD) ex vivo in an optical bench.

Methods : Human lenses were obtained from cadaver eyes that were rejected for corneal transplantation (Biobank Antwerp, Belgium, ID71030031000). Eyes were dissected and lenses were removed and incubated with FAOD (Creative enzymes) or PBS. Lens power was measured before treatment and up to 4 hr. Focal distance measurement is based on the thin lens formula 1/f=1/s1 + 1/s2 (f, focal distance of the lens; s1, object distance from the lens; s2, image distance from the lens). Magnification M of the optical system is M=S2/S1. By measuring the total distance between object and image plane L=S1+S2 and the magnification M, the focal distance of the lens-under-test is obtained L/f= (1+M)(1+1/M). As the focal distance of the lens-under-test is small (± 8 mm), a high resolution CMOS sensor was used (Basler ace - acA2000-165uc, 2040 x 1086 pixels and pixel size 5.5 µm) in combination with a fixed focal length imaging lens (25mm/F1.4 59871 Edmund optics, New Jersey). The object consisted of a periodic pattern of dark and white lines. Reference image was taken without the lens-under-test by placing the camera at the position with the image in focus. The lens-under-test was placed at random position from the object and the distance of the camera was repositioned such that the image of the object is in focus. Measurement method was verified by a known aspheric lens with focal distance 4.03 mm (Thorlabs C340TMD-A) resulting in an error of less than 1% on the focal length.

Results : Lens power at baseline was 17 ±0.95 D and did not change when treated with saline. Lens power was measured in air and converted to lens power in water (refractive index of lens in air is 1.5, refractive index of lens in water is 1.13). Lens power increased after 2 hours of FAOD treatment with 0.45 ± 0.35 D, after 3 hours of FAOD treatment with 0.96 ± 0.96 D and after 5 hours (maximum) with 2.11 ± 0.67. FAOD treatment of human lenses thus results in increased lens power.

Conclusions : FAOD treatment, but not PBS treatment, leads to gain of human lens power after 5-hours of incubation.These results indicate that FAOD could potentially be used to reverse presbyopia by deglycating lens proteins.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×